Replies to post #115379 on Biotech Values

[DewDiligence]

“We hold that claims 2, 3, 14, and 15 of the ’775 patent are invalid for lack of written description. The judgment below is reversed.”

Superb outcome for ABT. Investors do not seem to have noticed yet.